Johnson & Johnson has secured an exclusive option to acquire Sail Biomedicines for $2.58 billion, paying $785 million up front to advance its preclinical in vivo CAR-T pipeline. This deal highlights a broader pharmaceutical trend, with companies like Eli Lilly and Bristol Myers Squibb acquiring in vivo startups to bypass the costly laboratory cell manipulation required by traditional ex vivo therapies.
J&J Sail Biomedicines acquisition
- ▪Johnson & Johnson secured an exclusive option to acquire Sail Biomedicines for $2.58 billion.
- ▪Johnson & Johnson agreed to pay $785 million up front, including a $465 million equity investment, to advance Sail Biomedicines' lead program.
In vivo CAR-T technology
- ▪Traditional ex vivo CAR-T therapies require manipulating cells in a laboratory, which is a costly process that typically requires chemotherapy conditioning.
- ▪In vivo CAR-T technology aims to reprogram immune cells inside the body, offering a more accessible alternative to traditional ex vivo cell therapies.
Pharma in vivo acquisitions
- ▪Large pharmaceutical companies have acquired at least six startups focused on in vivo cell therapy technology since early 2025.
- ▪Major pharmaceutical companies, including Eli Lilly and Bristol Myers Squibb, have recently acquired in vivo cell therapy developers.
Sail Biomedicines pipeline
- ▪Sail Biomedicines was formed in 2023 through the merger of Senda Biosciences and Laronde, combining endless RNA and programmable nanoparticle technologies.
- ▪Sail Biomedicines' lead program, SAIL-0839, is in preclinical testing for undisclosed therapeutic targets.
- ▪Sail Biomedicines has four in vivo cell therapy programs in preclinical development.
J&J cell therapy portfolio
- ▪Johnson & Johnson previously partnered with Kelonia Therapeutics on in vivo CAR-T therapies before Kelonia Therapeutics was acquired by Eli Lilly.
- ▪Johnson & Johnson co-developed the multiple myeloma cell therapy Carvykti with Legend Biotech.
Story comments
Loading comments…